better medicines

for a better world

primum non nocere

"First, do no harm" is an often quoted and poorly understood credo used in medicine. believes that in modern medicine and medicinal treatment of disease this means that physician-recommended treatment involves a balance of risks and benefits, and that this balance should always favor the patient.

Whereas aims to minimize risks associated with the use of medicinal substances, we cannot rule out that adverse events may occur in a significant section of the population. sees patient education in regard to those risks as one of its wider missions. We want our customers and our patients to know that maintains a high ethical standard when making business decisions, and that known or anticipated adverse events of any of the medicines in our portfolio will be fully disclosed.

drug discovery and development

Drug discovery and development is an expensive and time-consuming enterprise. According to the Tufts Center for the Study of Drug Development, developing a new drug substance may take from 5 to 15 years, and cost as much as $1.2 billion.

These data are heavily skewed by the big pharmaceutical companies that target so-called "block-buster" drugs with annual revenue of $1 billion or more.

Many small pharmaceutical companies exist that focus on much smaller market segments. It is our experience that such smaller market segments can be developed at substantially reduced cost, although not necessarily proportionally smaller.

Small pharmaceutical companies, non-profit research organizations, and patient advocacy groups may find that gives them access to drug discovery and development capabilities for diseases that are not or under-represented in the portfolios of big pharmaceutical companies. has expertise in pediatric, immunological, cardiovascular, and central nervous system diseases. We currently focus on diseases with an established cause-effect relationship and readily accessible clinical models. As our company and network grows we expect to expand our knowledge base to other fields of medicine.

management philosophy

Many drug discovery and development organizations are focused on a particular disease mechanism or technology. They excel in their particular area of expertise, but may have limited exposure to and experience with the entire drug development process. employs total quality management and other business improvement techniques in order to streamline the drug discovery and development process and to maximize value for all of its stakeholders. Patients and physicians gain access to valuable medicines faster. Regulatory authorities, business partners, and our investors know they can rely on the accurate and complete data we provide. Our investors, business partners, and employees trust us to handle our finances wisely and effectively.

Better Medicines is not just a name, it's a philosophy!